uri icon
  • Contact Info
  • 1 979 845 7206

Maxwell, Steven Associate Professor


My primary interests include Cancer; Oncogenes; Tumor Suppressor; Genes Programmed Cell Death (apoptosis); Chemoresistance, and Angiogenesis. My laboratory studies mechanisms of evolution of chemoresistance in diffuse large B-cell lymphoma (DLBCL). One current primary objective is to conduct a Phase I study that (1) confirms RTI-79 safety in platinum-resistant/refractory ovarian cancer patients, and (2) demonstrates signals of efficacy in humans (ex: time-to-disease progression and changes in CA125 biomarker). A second objective is to better define the RTI-79 mechanism of action (MOA) by (1) determining how RTI-79 causes a rapid burst in superoxides, and (2) elucidating the basis of Nrf-2 pathway downregulation.

HR job title

  • Instructional Associate Professor